@article{392d4db1f004406b820bf4114005645d,
title = "Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients?",
keywords = "acute coronary syndrome, dual antiplatelet therapy, elderly, pharmacogenetics, PREDICTION RULE, CLOPIDOGREL, THERAPY, TICAGRELOR, VALIDATION, OUTCOMES",
author = "\{van den Broek\}, \{Wout W. A.\} and \{ten Berg\}, \{Jurrien M.\}",
note = "Funding Information: JM ten Berg reports grants from the Netherlands Organization for Health Research and Development, a Dutch government institution called ZonMw. JM ten Berg reports speaker fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, the Medicines Company, Accumetrics, Boehringer-Ingelheim, Bayer, BMS, Pfizer and Ferrer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.",
year = "2021",
month = aug,
doi = "10.2217/pgs-2021-0078",
language = "English",
volume = "22",
pages = "727--730",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Routledge/Taylor \& Francis Group",
number = "12",
}